OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

Authors: Kathryn Evans, JianXin Duan, Tara Pritchard, Connor D. Jones, Lisa McDermott, Zhaohui Gu, Cara E. Toscan, Narimanne El-Zein, Chelsea Mayoh, Stephen W. Erickson, Yuelong Guo, Fanying Meng, Donald Jung, Komal S. Rathi, Kathryn G. Roberts, Charles G. Mullighan, Chi-Sheng Shia, Tillman Pearce, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock

Published: 2019-04-23

DOI: 10.1158/1078-0432.ccr-19-0551

Source: Full article


Abstract

Abstract